Search Results - "Knorr, Katherine L B"

Leukemia stem cell gene expression signatures contribute to acute myeloid leukemia risk stratification by Knorr, Katherine L B, Goldberg, Aaron D

Get full text

Measurement of BH3-only protein tolerance by Dai, Haiming, Ding, Husheng, Peterson, Kevin L, Meng, X Wei, Schneider, Paula A, Knorr, Katherine L B, Kaufmann, Scott H

“…The BCL2 family of proteins regulates cellular life and death decisions. Among BCL2 family members, BH3-only proteins have critical roles by neutralizing…”
Get full text

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells by Yun, Seongseok, Vincelette, Nicole D., Knorr, Katherine L.B., Almada, Luciana L., Schneider, Paula A., Peterson, Kevin L., Flatten, Karen S., Dai, Haiming, Pratz, Keith W., Hess, Allan D., Smith, B.Douglas, Karp, Judith E., Hendrickson, Andrea E.Wahner, Fernandez-Zapico, Martin E., Kaufmann, Scott H.

“…The mammalian target of rapamycin (mTOR), a kinase that regulates proliferation and apoptosis, has been extensively evaluated as a therapeutic target in…”
Get full text

LeukeMYC prognostication by Knorr, Katherine L. B., Tallman, Martin S.

Get full text

Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment by Correia, Cristina, Lee, Sun-Hee, Meng, X. Wei, Vincelette, Nicole D., Knorr, Katherine L.B., Ding, Husheng, Nowakowski, Grzegorz S., Dai, Haiming, Kaufmann, Scott H.

“…Bcl-2, the founding member of a family of apoptotic regulators, was initially identified as the protein product of a gene that is translocated and…”
Get full text

Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo by Knorr, Katherine L.B., Finn, Laura E., Smith, B. Douglas, Hess, Allan D., Foran, James M., Karp, Judith E., Kaufmann, Scott H.

“…Current understanding suggests that malignant stem and progenitor cells must be reduced or eliminated for prolonged remissions in myeloid neoplasms such as…”
Get full text

Investigation of MLN4924 Alone and in Combination with Bcl-2 Inhibitors in Hematopoietic Stem Cells and Progenitors in Acute Myelogenous Leukemia by Knorr, Katherine L.B., Smith, B. Douglas, Hess, Allan D., Karp, Judith E., Kaufmann, Scott H.

“…MLN4924, a novel chemotherapeutic agent designed to inhibit the Nedd8 Activating Enzyme (NAE), has shown promise in early clinical testing in relapsed and…”
Get full text

mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies by Yun, Seongseok, Vincelette, Nicole D., Knorr, Katherine L.B., Almada, Luciana L., Schneider, Paula A., Peterson, Kevin L., Flatten, Karen S., Hess, Allan D., Smith, B. Douglas, Karp, Judith E., Fernandez-Zapico, Martin E., Kaufmann, Scott H.

“…The mammalian target of rapamycin (mTOR), a kinase that regulates proliferation and apoptosis, has been extensively evaluated as a therapeutic target in…”
Get full text

Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells From Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo by Knorr, Katherine L B, Finn, Laura E, Smith, B Douglas, Hess, Allan D, Foran, James M, Karp, Judith E, Kaufmann, Scott H

“…: Current understanding suggests that malignant stem and progenitor cells must be reduced or eliminated for prolonged remissions in myeloid neoplasms such as…”
Get full text